← Leaderboards
Mark S Klempner
Tufts Medical Center
$144,088,145
Attributed
$144,088,145
Total exposure
9
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $16M · FY2005–11$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$174,063,228 · 10
By mechanism
UC6$128,021,180 · 1
UC7$42,740,367 · 4
R01$1,972,250 · 1
N01$810,485 · 1
R21$433,468 · 1
M01$85,478 · 2
Top collaborators
No co-investigators on record.
Most similar at Tufts Medical Center
Same institution · by research overlap
- Linden T Hu$37,353,232
- Patricia L Hibberd$21,584,178
- Debbie Beasley$4,731,530
- Usamah S Kayyali$2,995,995
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchLyme DiseaseHuman SubjectEnvironmentHuman Therapy EvaluationClinical TrialsLaboratoriesMicroorganism Disease ChemotherapyCase HistoryInfectious Diseases ResearchCephalosporinsTetracyclinesDrug Screening /EvaluationAntibacterial AgentsChronic Disease /DisorderBorreliaNeuropsychological TestsQuality Of LifeBiodefenseEmergency SituationInstitutesAwardCategoriesEnvironmental Health
Grant awards (31)
Administrative Core$1,161,614
UC7 · FY2011 · AI · contact PI
Administrative Core$867,758
UC7 · FY2010 · AI · contact PI
Environmental Health and Safety Core$867,756
UC7 · FY2010 · AI · contact PI
National Emerging Infectious Diseases Laboratories Operations$11,010,956
UC7 · FY2009 · AI · contact PI
Administrative Core$1,835,164
UC7 · FY2009 · AI · contact PI
Environmental Health and Safety Core$1,835,159
UC7 · FY2009 · AI · contact PI
National Emerging Infectious Diseases Laboratories Operations$12,000,000
UC7 · FY2008 · AI · contact PI
Administrative Core$2,000,004
UC7 · FY2008 · AI · contact PI
Environmental Health and Safety Core$1,999,999
UC7 · FY2008 · AI · contact PI
National Emerging Infectious Diseases Laboratories Operations$6,250,000
UC7 · FY2007 · AI · contact PI
Environmental Health and Safety Core$1,119,260
UC7 · FY2007 · AI · contact PI
Administrative Core$653,701
UC7 · FY2007 · AI · contact PI
National Emerging Infectious Diseases Laboratories Operations$714,127
UC7 · FY2006 · AI · contact PI
Administrative Core$333,107
UC7 · FY2006 · AI · contact PI
Environmental Health and Safety Core$91,762
UC7 · FY2006 · AI · contact PI
Lyme Disease: Spirochete Invasion and Host Immunity$402,500
R01 · FY2005 · AI
Lyme Disease: Spirochete Invasion and Host Immunity$402,500
R01 · FY2004 · AI
National Center/Emerging Infectous Diseases &Biodefense$128,021,180
UC6 · FY2003 · AI
Lyme Disease: Spirochete Invasion and Host Immunity$402,500
R01 · FY2003 · AI
New Method for Detecting Bacillus Anthracis Spores$216,368
R21 · FY2003 · AI
Lyme Disease: Spirochete Invasion and Host Immunity$402,500
R01 · FY2002 · AI
New Method for Detecting Bacillus Anthracis Spores$217,100
R21 · FY2002 · AI
CEFTRIAXONE AND DOXYCYCLINE IN PATIENTS WITH SERONEGATIVE CHRONIC LYME DISEASE$0
M01 · FY2002 · RR
CEFTRIAXONE &DOXYCYCLINE IN PATIENTS WITH SEROPOSITIVE CHRONIC POST LYME DISEASE$0
M01 · FY2002 · RR
Lyme Disease: Spirochete Invasion and Host Immunity$362,250
R01 · FY2001 · AI
CEFTRIAXONE &DOXYCYCLINE IN PATIENTS WITH SEROPOSITIVE CHRONIC POST LYME DISEASE$0
M01 · FY2001 · RR
CEFTRIAXONE AND DOXYCYCLINE IN PATIENTS WITH SERONEGATIVE CHRONIC LYME DISEASE$0
M01 · FY2001 · RR
CLINICAL STUDIES OF CHRONIC LYME DISEASE$700,000
N01 · FY2000 · AI
CLINICAL STUDIES OF CHRONIC LYME DISEASE$110,485
N01 · FY2000 · AI
CEFTRIAXONE &DOXYCYCLINE IN PATIENTS WITH SEROPOSITIVE CHRONIC POST LYME DISEASE$42,739
M01 · FY2000 · RR
CEFTRIAXONE AND DOXYCYCLINE IN PATIENTS WITH SERONEGATIVE CHRONIC LYME DISEASE$42,739
M01 · FY2000 · RR